Growth and expansion for Aptamer Group in 2022
As we come to the end of 2022 and our first year as a listed company, the year in review shows a clear theme of growth and expansion across…
As we come to the end of 2022 and our first year as a listed company, the year in review shows a clear theme of growth and expansion across…
Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…
The ability to continuously monitor the concentration of specific molecules in the body is a long-sought goal of biomedical research. For this purpose, interstitial fluid (ISF) was proposed as…
Novel diagnostic platforms are bringing possibilities for improved patient care and reduced healthcare costs. We spoke with Dr Edgar Goluch, the CEO and founder of QSM Diagnostics,
Arron Tolley, CEO of Aptamer Group discusses the teams progress on COVID-19 tests: 17/06/2020 Scientists at York-based biotechnology company Aptamer Group are using their expertise to develop a COVID-19…
22nd June 2018 Introduction: Changes in hormone levels can be key indicators to a variety of issues, examples include testosterone levels in general health and well being(1)…